Sickle Cell Disease Trial, Recruiting (NCT06318143)

Sickle Cell Disease Trial, Recruiting NCT06318143 Sponsor: New York University Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06318143 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older with Sickle Cell Disease (SCD) who have given their written consent to participate
Children with SCD aged 12 months to 17 years whose guardian is present and has given consent, or who have given their own agreement (assent) to participate
People whose medical records are registered in the local electronic health records system and who have received care at a participating clinic or health facility
People who are not currently taking a medication called hydroxyurea (HU)
People with specific SCD genetic types: SCD-SS, SCD-Sβ0 thalassaemia, or SCD-SOArab (in some cases, a person with SCD-SC who is severely affected may be considered for the trial under a modified treatment plan, assessed individually by the trial site)

Who may not be able to join:

People with SCD whose medical records are not registered in the local electronic health records system, or who have not provided consent or assent
People who are physically unable to take part in the study activities
People who are already taking hydroxyurea (HU)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 212-992-6085

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06318143

Sponsor: New York University

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: 212-992-6085

More information: https://clinicaltrials.gov/study/NCT06318143

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older with Sickle Cell Disease (SCD) who have given their written consent to participate
Children with SCD aged 12 months to 17 years whose guardian is present and has given consent, or who have given their own agreement (assent) to participate
People whose medical records are registered in the local electronic health records system and who have received care at a participating clinic or health facility
People who are not currently taking a medication called hydroxyurea (HU)
People with specific SCD genetic types: SCD-SS, SCD-Sβ0 thalassaemia, or SCD-SOArab (in some cases, a person with SCD-SC who is severely affected may be considered for the trial under a modified treatment plan, assessed individually by the trial site)

Who may not be able to join:

People with SCD whose medical records are not registered in the local electronic health records system, or who have not provided consent or assent
People who are physically unable to take part in the study activities
People who are already taking hydroxyurea (HU)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

New York University

Registry

ClinicalTrials.gov

Start date

1 July 2024

Est. completion

30 June 2027

Where this trial is recruiting

Nigeria

Primary endpoints

Patient numbers - screening; Patient numbers - proportion on HU; Patient numbers - dosage

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov